[go: up one dir, main page]

WO1994011508A3 - Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods - Google Patents

Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods Download PDF

Info

Publication number
WO1994011508A3
WO1994011508A3 PCT/US1993/011316 US9311316W WO9411508A3 WO 1994011508 A3 WO1994011508 A3 WO 1994011508A3 US 9311316 W US9311316 W US 9311316W WO 9411508 A3 WO9411508 A3 WO 9411508A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
hybrid
cells
fab
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/011316
Other languages
French (fr)
Other versions
WO1994011508A2 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Fund of Contra Costa
Original Assignee
Cancer Research Fund of Contra Costa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Fund of Contra Costa filed Critical Cancer Research Fund of Contra Costa
Priority to AU56155/94A priority Critical patent/AU5615594A/en
Publication of WO1994011508A2 publication Critical patent/WO1994011508A2/en
Publication of WO1994011508A3 publication Critical patent/WO1994011508A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A polypeptide consists of a variable region of the light or heavy chains of an antibody of a species selectively binding the human mammary fat globule (HMFG) antigen, and an antigen found on the surface or the cytoplasm of tumor cells such as carcinoma cells or that is released by the cells, combinations thereof operatively linked to one another, and mixtures thereof. The polypeptide may be glycosylated. A hybrid polypeptide comprises the polypeptide of the invention and an effector agent, and both polypeptides may be present as a composition with a non-proteolytic carrier as well as with a pharmaceutically acceptable carrier. Diagnostic kits comprises the polypeptide or hybrid polypeptide of the invention and other components such as anti-tumor antibody, and anti-constant region immunoglobulin, protein G or A, a solid support, and instructions for their use. Tumors may be imaged and/or diagnosed in vivo by administering the radiolabeled polypeptide of this invention and detecting any localized labeled polypeptide, and in vitro by contacting a biological sample with the hybrid polypeptide of the invention to form a complex with neoplastic antigen present in the sample, and detecting any complex formed. The growth or the size of a primary or metastasized tumor may be therapeutically inhibited or reduced by administering the polypeptide or hybrid polypeptide of the invention. A polynucleotide comprises an oligonucleotide encoding the polypeptide or hybrid polypeptide described above, hybrid vectors carry the polydeoxyribonucleotide(s) of the invention, and host cells are transfected with the hybrid vectors. Te polypeptide or hybrid polypeptide may be obtained by cloning one or more of the polydeoxyribonucleotide(s) of this invention. An anti-idiotype polypeptide comprises polyclonal antibodies raised against the polypeptide of this invention; monoclonal antibodies thereof; Fab, Fab', (Fab')2, and variable region fragments thereof; an oligopeptide comprising the amino acid sequence APDTRPA or tandem repeats thereof, combinations thereof and mixtures thereof. The hybrid polypeptide may also contain an effector agent and be provided as an anti-neoplastic vaccine in a vaccination kit. The serum concentration of a circulating polypeptide that binds to an antigen present on the surface or in the cytoplasm of tumor cells or that are released by the cells may be lowered by administering the anti-idiotype polypeptide of the invention to accelerate the clearance of the polypeptide.
PCT/US1993/011316 1992-11-13 1993-11-15 Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods Ceased WO1994011508A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56155/94A AU5615594A (en) 1992-11-13 1993-11-15 Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97770792A 1992-11-13 1992-11-13
US97770692A 1992-11-13 1992-11-13
US07/977,706 1992-11-13
US07/977,707 1992-11-13
US12801593A 1993-09-28 1993-09-28
US08/128,015 1993-09-28

Publications (2)

Publication Number Publication Date
WO1994011508A2 WO1994011508A2 (en) 1994-05-26
WO1994011508A3 true WO1994011508A3 (en) 1994-07-07

Family

ID=27383656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011316 Ceased WO1994011508A2 (en) 1992-11-13 1993-11-15 Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods

Country Status (2)

Country Link
AU (1) AU5615594A (en)
WO (1) WO1994011508A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
AU782569B2 (en) * 1999-08-18 2005-08-11 Oncoquest Inc. Therapeutic binding agents against MUC-1 antigen and methods of their use
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
ES2459018T3 (en) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Close junction effector formulations
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
CN112694521B (en) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 A kind of artificial polypeptide LH, its antibody and its application in pathological detection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002945A1 (en) * 1984-11-09 1986-05-22 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1990005142A1 (en) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
WO1990012319A1 (en) * 1989-04-05 1990-10-18 John Muir Cancer & Aging Institute Monoclonal antibody recognizing a glycoprotein of human milk-fat globule membrane mucin antigen
WO1992004380A1 (en) * 1990-09-07 1992-03-19 Unilever Plc Specific binding agents
WO1992007939A2 (en) * 1990-11-01 1992-05-14 John Muir Cancer & Research Institute Polypeptide with 46kd hmfg differentiation antigen binding specificity
EP0534742A1 (en) * 1991-09-26 1993-03-31 Celltech Therapeutics Limited Anti-human milk fat globule humanised antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002945A1 (en) * 1984-11-09 1986-05-22 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1990005142A1 (en) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
WO1990012319A1 (en) * 1989-04-05 1990-10-18 John Muir Cancer & Aging Institute Monoclonal antibody recognizing a glycoprotein of human milk-fat globule membrane mucin antigen
WO1992004380A1 (en) * 1990-09-07 1992-03-19 Unilever Plc Specific binding agents
WO1992007939A2 (en) * 1990-11-01 1992-05-14 John Muir Cancer & Research Institute Polypeptide with 46kd hmfg differentiation antigen binding specificity
EP0534742A1 (en) * 1991-09-26 1993-03-31 Celltech Therapeutics Limited Anti-human milk fat globule humanised antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. DIENHART ET AL.: "Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen.", CANCER RESEARCH, vol. 50, no. 21, 1 November 1990 (1990-11-01), PHILADELPHIA PA, USA, pages 7068 - 7076 *
E. BLANK ET AL.: "A novel anti-breast epithelial mucin Mab (BrE-3). Characterization and experimental biodistribution and immunotherapy.", CANCER JOURNAL, vol. 5, no. 1, 1992, VILLEJUIF, FRANCE, pages 38 - 44 *
J. COUTO ET AL.: "Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.", HYBRIDOMA, vol. 12, no. 1, February 1993 (1993-02-01), NEW YORK, USA, pages 15 - 23 *
S. STARK ET AL.: "Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, 1991, NEW YORK, USA, pages 613 - 624 *

Also Published As

Publication number Publication date
AU5615594A (en) 1994-06-08
WO1994011508A2 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
Marcus et al. Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoadsorbents
Wagener et al. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: a systematic approach for the determination of epitope specificities of monoclonal antibodies.
Frankel et al. Monoclonal antibodies to a human prostate antigen
Walter et al. Antibodies specific for the carboxy-and amino-terminal regions of simian virus 40 large tumor antigen.
Hand et al. Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.
Colcher et al. Prolonged binding of a radiolabeled monoclonal antibody (B72. 3) used for the in situ radioimmunodetection of human colon carcinoma xenografts
US4446122A (en) Purified human prostate antigen
Kuhajda et al. Expression of haptoglobin-related protein and its potential role as a tumor antigen.
Collatz et al. Further investigations of circulating antibodies in colon cancer patients: on the autoantigenicity of the carcinoembryonic antigen
MX9705610A (en) MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY.
JPH08266273A (en) Hybridoma producing anti-human breast cancer monoclonal antibody
Yoshida et al. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas
WO1994011508A3 (en) Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
CA2325605A1 (en) Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein said peptides bind to mhc class i and mhc class ii molecules, and uses thereof
JPH11512818A (en) Tumor-specific P450 protein
EP0454782B1 (en) Cancer related haptoglobin (hpr)
WO1994011509A3 (en) Peptides and anti-sense peptides with broad neoplastic specificity
Wagener et al. Binding of five monoclonal anti‐CEA antibodies with different epitope specifities to various carcinoma tissues
JPH10502814A (en) Proteins from mammalian liver and their use in oncology
Bhattacharya et al. Identification of a human cancer-associated antigen defined with monoclonal antibody
JPS61289897A (en) Novel tumor relating antigen
Jeppsson et al. Tumour and cellular localization by use of monoclonal and polyclonal antibodies to placental alkaline phosphatase
Gold et al. Murine monoclonal antibodies to colon-specific antigen p
Bourne et al. Monoclonal antibodies M340 and UJ181. 4 recognize antigens associated with primitive neuroectodermal tumours/tissues
AU725682B2 (en) Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA